| Ulcerative Colitis
Entyvio vs Velsipity
Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.Deep comparison between: Entyvio vs Velsipity with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVelsipity has a higher rate of injection site reactions vs Entyvio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Velsipity but not Entyvio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Entyvio
Velsipity
At A Glance
IV infusion or SC injection
Every 2 weeks (SC) or every 8 weeks (IV)
alpha4beta7 integrin antagonist
Oral
Daily
S1P receptor modulator
Indications
- Ulcerative Colitis
- Crohn Disease
- Ulcerative Colitis
Dosing
Ulcerative Colitis, Crohn Disease Week 0 and Week 2: 300 mg IV infusion over approximately 30 minutes; Week 6 onwards: 300 mg IV infusion every 8 weeks or 108 mg SC injection every 2 weeks; discontinue if no evidence of therapeutic benefit by Week 14.
Ulcerative Colitis 2 mg orally once daily; swallow tablet whole, with or without food.
Contraindications
- Known serious or severe hypersensitivity reaction to vedolizumab or any excipient (e.g., dyspnea, bronchospasm, urticaria, flushing, rash, increased heart rate)
- Myocardial infarction, unstable angina pectoris, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure within the last 6 months
- History or presence of Mobitz type II second-degree or third-degree AV block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker
Adverse Reactions
Most common (>=3%) nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities
Serious infusion-related reactions including anaphylaxis, infections (anal abscess, sepsis, tuberculosis, Listeria meningitis, giardiasis, cytomegaloviral colitis), liver injury (elevated transaminases, hepatitis), malignancies
Postmarketing anaphylaxis, acute pancreatitis, interstitial lung disease, pneumonitis
Most common (>=2%) Headache, elevated liver tests, dizziness, arthralgia, hypertension, urinary tract infection, nausea, hypercholesterolemia, herpes viral infection, bradycardia
Serious Infections, bradyarrhythmia and atrioventricular conduction delays, liver injury, macular edema, increased blood pressure, fetal risk, cutaneous malignancies, posterior reversible encephalopathy syndrome, respiratory effects
Pharmacology
Vedolizumab is a humanized IgG1 monoclonal antibody that specifically binds to the alpha4beta7 integrin and blocks its interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1), inhibiting the migration of memory T-lymphocytes into inflamed gastrointestinal tissue; the mechanism is gut-selective and does not affect the alpha4beta1 or alphaEbeta7 integrins or VCAM-1 interactions.
Etrasimod is a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1, 4, and 5, partially and reversibly blocking lymphocyte egress from lymphoid organs, thereby reducing peripheral blood lymphocyte counts and potentially limiting lymphocyte migration into the intestines.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Entyvio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Velsipity
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Entyvio
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Velsipity
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Entyvio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Velsipity
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Crohn's Disease: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Ulcerative Colitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EntyvioView full Entyvio profile
VelsipityView full Velsipity profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.